236 related articles for article (PubMed ID: 27494912)
21. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
van de Sande WW; Mathot RA; ten Kate MT; van Vianen W; Tavakol M; Rijnders BJ; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2009 May; 53(5):2005-13. PubMed ID: 19237647
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis.
Martin-Vicente A; Capilla J; Guarro J
Med Mycol; 2017 Jun; 55(4):457-460. PubMed ID: 27760829
[TBL] [Abstract][Full Text] [Related]
23. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
Galiger C; Brock M; Jouvion G; Savers A; Parlato M; Ibrahim-Granet O
Antimicrob Agents Chemother; 2013 Jul; 57(7):3046-59. PubMed ID: 23587947
[TBL] [Abstract][Full Text] [Related]
24. Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.
Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5438-47. PubMed ID: 23959322
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
Liu P; Mould DR
Antimicrob Agents Chemother; 2014 Aug; 58(8):4727-36. PubMed ID: 24914120
[TBL] [Abstract][Full Text] [Related]
26. Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology.
Cafini F; Sevillano D; Alou L; Gómez-Aguado F; Corcuera MT; González N; Guinea J; Prieto J
Rev Esp Quimioter; 2012 Mar; 25(1):47-55. PubMed ID: 22488542
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
Liu P; Mould DR
Antimicrob Agents Chemother; 2014 Aug; 58(8):4718-26. PubMed ID: 24913161
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
[TBL] [Abstract][Full Text] [Related]
29. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.
Perkhofer S; Jost D; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2008 May; 52(5):1873-5. PubMed ID: 18347112
[TBL] [Abstract][Full Text] [Related]
31. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.
Verweij PE; Ananda-Rajah M; Andes D; Arendrup MC; Brüggemann RJ; Chowdhary A; Cornely OA; Denning DW; Groll AH; Izumikawa K; Kullberg BJ; Lagrou K; Maertens J; Meis JF; Newton P; Page I; Seyedmousavi S; Sheppard DC; Viscoli C; Warris A; Donnelly JP
Drug Resist Updat; 2015; 21-22():30-40. PubMed ID: 26282594
[TBL] [Abstract][Full Text] [Related]
32. Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.
Calvo E; Pastor FJ; Salas V; Mayayo E; Guarro J
Mycopathologia; 2012 Apr; 173(4):251-7. PubMed ID: 22139415
[TBL] [Abstract][Full Text] [Related]
33. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients.
Fuhren J; Voskuil WS; Boel CH; Haas PJ; Hagen F; Meis JF; Kusters JG
J Antimicrob Chemother; 2015 Oct; 70(10):2894-8. PubMed ID: 26163402
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.
Huurneman LJ; Neely M; Veringa A; Docobo Pérez F; Ramos-Martin V; Tissing WJ; Alffenaar JW; Hope W
Antimicrob Agents Chemother; 2016 Apr; 60(4):2336-42. PubMed ID: 26833158
[TBL] [Abstract][Full Text] [Related]
35. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
[TBL] [Abstract][Full Text] [Related]
36. Assessment of carvacrol for control of avian aspergillosis in intratracheally challenged chickens in comparison to voriconazole with a reference on economic impact.
Tartor YH; Hassan FAM
J Appl Microbiol; 2017 Nov; 123(5):1088-1099. PubMed ID: 28795522
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.
Rudramurthy SM; Seyedmousavi S; Dhaliwal M; Chakrabarti A; Meis JF; Mouton JW
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821453
[TBL] [Abstract][Full Text] [Related]
38. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
Mavridou E; Bruggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
[TBL] [Abstract][Full Text] [Related]
39. A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.
Wang T; Zhang T; Meng T; Li Y; Chen L; Yang Q; Dong H; Lei J; Chen L; Dong Y
J Transl Med; 2018 Jun; 16(1):157. PubMed ID: 29880050
[TBL] [Abstract][Full Text] [Related]
40. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
